Bruker Corporation filed a Form 8-K on November 16, 2026, disclosing the appointment of Eicke Latz MD PhD to its Board of Directors effective January 1, 2027, and the declaration of a quarterly cash dividend of $0.05 per share on its common stock.
Key Highlights
- New Director: Eicke Latz MD PhD was appointed to Bruker's Board of Directors, effective January 1, 2027, filling a newly created vacancy in Class II.
- Board Expansion: The Board approved an increase in its size by one director, bringing the total number of directors to twelve.
- Initial Term: Dr. Latz will initially serve as a director until the 2029 Annual Meeting of Stockholders.
- Quarterly Dividend: The Board declared a quarterly cash dividend of $0.05 per share on the company's common stock, $0.01 par value per share.
- Dividend Dates: The dividend was declared on November 12, 2026, payable January 7, 2027, to shareholders of record at the close of business on December 21, 2026.
- No Special Arrangements: According to the filing, there are no arrangements or understandings between Dr. Latz and any other person pursuant to which he was elected, and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
Bruker Expands Board to Twelve Directors and Names Dr. Latz
Bruker Corporation (NASDAQ:BRKR) disclosed in its November 16, 2026 Form 8-K that its Board of Directors, on November 13, 2026, approved expanding board membership by one seat to reach a total of twelve directors. The newly created seat was assigned to Class II, and Eicke Latz MD PhD was appointed to fill it, with his service beginning January 1, 2027. According to the filing, Dr. Latz will initially serve until the company's 2029 Annual Meeting of Stockholders.
The filing states that Dr. Latz's director compensation "will be consistent with that of the other non-employee directors of the Company," as described in the company's definitive proxy statement for the 2026 Annual Meeting of Stockholders, which was filed with the SEC on April 10, 2026. Bruker also disclosed that it will file an amended Form 8-K to report Dr. Latz's committee assignments once they are determined.
Separately, the filing reported that the Board declared a quarterly cash dividend of $0.05 per share on Bruker's common stock. The dividend was declared on November 12, 2026, and is payable on January 7, 2027, to shareholders of record as of the close of business on December 21, 2026. The filing was signed by Thomas M. Bures, Chief Accounting Officer, on behalf of the registrant.
What Was Disclosed
Bruker Corporation reported the election of Eicke Latz MD PhD to its Board of Directors effective January 1, 2027, expanding the board to twelve members, and declared a quarterly common stock cash dividend of $0.05 per share payable January 7, 2027.




Please wait processing your request...